First Trust Advisors LP purchased a new stake in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 29,256 shares of the biopharmaceutical company’s stock, valued at approximately $360,000.
A number of other hedge funds also recently made changes to their positions in LXRX. Morgan Stanley increased its position in shares of Lexicon Pharmaceuticals by 22.7% in the first quarter. Morgan Stanley now owns 174,765 shares of the biopharmaceutical company’s stock valued at $2,505,000 after buying an additional 32,276 shares in the last quarter. Credit Suisse AG increased its position in shares of Lexicon Pharmaceuticals by 27.5% in the first quarter. Credit Suisse AG now owns 92,548 shares of the biopharmaceutical company’s stock valued at $1,327,000 after buying an additional 19,978 shares in the last quarter. Pictet Asset Management Ltd. increased its position in shares of Lexicon Pharmaceuticals by 10.4% in the second quarter. Pictet Asset Management Ltd. now owns 67,950 shares of the biopharmaceutical company’s stock valued at $941,000 after buying an additional 6,400 shares in the last quarter. Schwab Charles Investment Management Inc. increased its position in shares of Lexicon Pharmaceuticals by 0.9% in the second quarter. Schwab Charles Investment Management Inc. now owns 193,318 shares of the biopharmaceutical company’s stock valued at $3,181,000 after buying an additional 1,633 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale purchased a new stake in shares of Lexicon Pharmaceuticals during the second quarter worth approximately $2,365,000.
LXRX has been the subject of several research reports. Needham & Company LLC reiterated a “buy” rating and set a $21.00 price target on shares of Lexicon Pharmaceuticals in a research report on Sunday, September 17th. Zacks Investment Research upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, November 14th. Wedbush reissued an “outperform” rating and set a $38.00 price objective on shares of Lexicon Pharmaceuticals in a research note on Thursday, November 30th. Finally, ValuEngine lowered Lexicon Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Sunday. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. Lexicon Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $28.50.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) traded up $0.24 on Tuesday, reaching $10.12. The company had a trading volume of 615,727 shares, compared to its average volume of 559,600. Lexicon Pharmaceuticals, Inc. has a 1 year low of $8.07 and a 1 year high of $18.00. The company has a current ratio of 1.66, a quick ratio of 1.65 and a debt-to-equity ratio of 1.09. The firm has a market cap of $1,070.00, a price-to-earnings ratio of -7.97 and a beta of 0.08.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.07. Lexicon Pharmaceuticals had a negative return on equity of 111.68% and a negative net margin of 165.69%. The company had revenue of $26.94 million for the quarter, compared to the consensus estimate of $27.97 million. During the same quarter in the prior year, the business earned ($0.35) EPS. Lexicon Pharmaceuticals’s revenue was down 2.8% on a year-over-year basis. research analysts anticipate that Lexicon Pharmaceuticals, Inc. will post -1.38 earnings per share for the current year.
In other news, CEO Lonnel Coats bought 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 15th. The stock was purchased at an average cost of $9.91 per share, with a total value of $99,100.00. Following the transaction, the chief executive officer now directly owns 42,985 shares in the company, valued at $425,981.35. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Public Equities L.P. Invus bought 145,680 shares of the firm’s stock in a transaction that occurred on Friday, November 10th. The stock was purchased at an average cost of $9.74 per share, with a total value of $1,418,923.20. The disclosure for this purchase can be found here. In the last quarter, insiders bought 914,353 shares of company stock worth $8,916,253. Company insiders own 5.77% of the company’s stock.
Lexicon Pharmaceuticals Company Profile
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.